CA2405946A1 - Procedes et compositions servant a traiter des etats fibreux et l'alteration de la fonction pulmonaire, et a ameliorer la production de lymphocyte - Google Patents
Procedes et compositions servant a traiter des etats fibreux et l'alteration de la fonction pulmonaire, et a ameliorer la production de lymphocyte Download PDFInfo
- Publication number
- CA2405946A1 CA2405946A1 CA002405946A CA2405946A CA2405946A1 CA 2405946 A1 CA2405946 A1 CA 2405946A1 CA 002405946 A CA002405946 A CA 002405946A CA 2405946 A CA2405946 A CA 2405946A CA 2405946 A1 CA2405946 A1 CA 2405946A1
- Authority
- CA
- Canada
- Prior art keywords
- uteroglobin
- cells
- patient
- recombinant human
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 316
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 77
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 43
- 230000004199 lung function Effects 0.000 title claims abstract description 25
- 230000003176 fibrotic effect Effects 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 title claims description 120
- 230000001771 impaired effect Effects 0.000 title description 3
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 claims abstract description 350
- 108090000203 Uteroglobin Proteins 0.000 claims abstract description 346
- 102000003848 Uteroglobin Human genes 0.000 claims abstract description 345
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 195
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 186
- 210000004369 blood Anatomy 0.000 claims abstract description 65
- 239000008280 blood Substances 0.000 claims abstract description 65
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 49
- 230000021164 cell adhesion Effects 0.000 claims abstract description 42
- 238000001727 in vivo Methods 0.000 claims abstract description 30
- 230000005012 migration Effects 0.000 claims abstract description 29
- 238000013508 migration Methods 0.000 claims abstract description 29
- 230000004054 inflammatory process Effects 0.000 claims abstract description 23
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 19
- 238000006213 oxygenation reaction Methods 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 273
- 102000004169 proteins and genes Human genes 0.000 claims description 178
- 108090000623 proteins and genes Proteins 0.000 claims description 178
- 230000000694 effects Effects 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 43
- 102000005962 receptors Human genes 0.000 claims description 42
- 108020003175 receptors Proteins 0.000 claims description 42
- 210000001519 tissue Anatomy 0.000 claims description 42
- 230000035755 proliferation Effects 0.000 claims description 39
- 230000003993 interaction Effects 0.000 claims description 38
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 37
- 239000002243 precursor Substances 0.000 claims description 37
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 36
- 230000002401 inhibitory effect Effects 0.000 claims description 36
- 239000003085 diluting agent Substances 0.000 claims description 35
- 238000000338 in vitro Methods 0.000 claims description 34
- 230000001404 mediated effect Effects 0.000 claims description 33
- 230000001419 dependent effect Effects 0.000 claims description 32
- 239000003937 drug carrier Substances 0.000 claims description 32
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 31
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 31
- 230000027455 binding Effects 0.000 claims description 31
- 230000001105 regulatory effect Effects 0.000 claims description 31
- 210000000440 neutrophil Anatomy 0.000 claims description 30
- 230000001413 cellular effect Effects 0.000 claims description 28
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 25
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
- 230000007423 decrease Effects 0.000 claims description 24
- 210000002744 extracellular matrix Anatomy 0.000 claims description 24
- 102100026918 Phospholipase A2 Human genes 0.000 claims description 22
- 101710096328 Phospholipase A2 Proteins 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 21
- 230000009545 invasion Effects 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 21
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 20
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 19
- 102000002090 Fibronectin type III Human genes 0.000 claims description 18
- 108050009401 Fibronectin type III Proteins 0.000 claims description 18
- 210000001616 monocyte Anatomy 0.000 claims description 18
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 17
- 230000033115 angiogenesis Effects 0.000 claims description 17
- 210000000224 granular leucocyte Anatomy 0.000 claims description 17
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- -1 inhaled pollens Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 210000003979 eosinophil Anatomy 0.000 claims description 16
- 210000003651 basophil Anatomy 0.000 claims description 15
- 230000008021 deposition Effects 0.000 claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 15
- 210000004969 inflammatory cell Anatomy 0.000 claims description 15
- 210000002540 macrophage Anatomy 0.000 claims description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 14
- 102000006495 integrins Human genes 0.000 claims description 14
- 108010044426 integrins Proteins 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 230000003247 decreasing effect Effects 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 230000037361 pathway Effects 0.000 claims description 13
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 12
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 12
- 210000003714 granulocyte Anatomy 0.000 claims description 12
- 210000000822 natural killer cell Anatomy 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000002889 endothelial cell Anatomy 0.000 claims description 10
- 210000003593 megakaryocyte Anatomy 0.000 claims description 10
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 230000019305 fibroblast migration Effects 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 9
- 230000004060 metabolic process Effects 0.000 claims description 9
- 230000008728 vascular permeability Effects 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 7
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 7
- 210000002216 heart Anatomy 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- 108010073385 Fibrin Proteins 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 230000010417 nitric oxide pathway Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 239000013566 allergen Substances 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- 210000001772 blood platelet Anatomy 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000019522 cellular metabolic process Effects 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 239000002085 irritant Substances 0.000 claims description 4
- 231100000021 irritant Toxicity 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 239000013618 particulate matter Substances 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 231100000719 pollutant Toxicity 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 230000002040 relaxant effect Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 102000000412 Annexin Human genes 0.000 claims description 2
- 108050008874 Annexin Proteins 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010005042 Bladder fibrosis Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000007885 bronchoconstriction Effects 0.000 claims description 2
- 229940030156 cell vaccine Drugs 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 238000013507 mapping Methods 0.000 claims description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 210000003061 neural cell Anatomy 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000006916 protein interaction Effects 0.000 claims description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 210000000678 band cell Anatomy 0.000 claims 18
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000008384 ileus Diseases 0.000 claims 1
- 201000010727 rectal prolapse Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 abstract description 12
- 210000002865 immune cell Anatomy 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 235000018102 proteins Nutrition 0.000 description 147
- 241001465754 Metazoa Species 0.000 description 106
- 210000004072 lung Anatomy 0.000 description 73
- 239000004094 surface-active agent Substances 0.000 description 43
- 239000012530 fluid Substances 0.000 description 38
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 36
- 239000002953 phosphate buffered saline Substances 0.000 description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 28
- 239000002158 endotoxin Substances 0.000 description 26
- 239000001301 oxygen Substances 0.000 description 26
- 229910052760 oxygen Inorganic materials 0.000 description 26
- 210000002700 urine Anatomy 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 229920006008 lipopolysaccharide Polymers 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- 102100031083 Uteroglobin Human genes 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 19
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 241000282412 Homo Species 0.000 description 14
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000283903 Ovis aries Species 0.000 description 12
- 241000700157 Rattus norvegicus Species 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 210000004291 uterus Anatomy 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 208000004852 Lung Injury Diseases 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000002460 smooth muscle Anatomy 0.000 description 9
- 210000005166 vasculature Anatomy 0.000 description 9
- 108091006112 ATPases Proteins 0.000 description 8
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010069363 Traumatic lung injury Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 231100000515 lung injury Toxicity 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 101000966253 Mus musculus Protein LMBR1L Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 229940063649 survanta Drugs 0.000 description 7
- 238000009423 ventilation Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 6
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 description 6
- 206010059033 Neonatal aspiration Diseases 0.000 description 6
- 102000002067 Protein Subunits Human genes 0.000 description 6
- 108010001267 Protein Subunits Proteins 0.000 description 6
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 210000003953 foreskin Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 206010038687 Respiratory distress Diseases 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 210000000621 bronchi Anatomy 0.000 description 5
- 210000003123 bronchiole Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000010595 endothelial cell migration Effects 0.000 description 5
- 230000035557 fibrillogenesis Effects 0.000 description 5
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 210000000066 myeloid cell Anatomy 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010015866 Extravasation Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 108010031318 Vitronectin Proteins 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000036251 extravasation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000004118 muscle contraction Effects 0.000 description 4
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 4
- 230000009325 pulmonary function Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 210000003995 blood forming stem cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000005732 intercellular adhesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000516 lung damage Toxicity 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000000399 optical microscopy Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 2
- 101100342994 Arabidopsis thaliana IIL1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 description 2
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001006 meconium Anatomy 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 206010061688 Barotrauma Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000265913 Crataegus laevigata Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108060004056 Integrin alpha Chain Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007807 Matrigel invasion assay Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000777235 Mus musculus Uteroglobin Proteins 0.000 description 1
- 101001059625 Mytilus californianus Fibronectin type III domain-containing protein Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000006447 Phospholipases A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010030304 Progesterone-Binding Globulin Proteins 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 101000777244 Rattus norvegicus Uteroglobin Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 108010001122 alpha(2)-microglobulin Proteins 0.000 description 1
- 230000004859 alveolar capillary barrier Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000012398 clinical drug development Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000002871 fertility agent Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000017777 integrin alpha chain Human genes 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000005064 nitric oxide mediated signal transduction Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008817 pulmonary damage Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000019705 regulation of vascular permeability Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000013417 toxicology model Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54992600A | 2000-04-14 | 2000-04-14 | |
| US09/549,926 | 2000-04-14 | ||
| PCT/US2001/012126 WO2001079285A1 (fr) | 2000-04-14 | 2001-04-13 | Procedes et compositions servant a traiter des etats fibreux et l'alteration de la fonction pulmonaire, et a ameliorer la production de lymphocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2405946A1 true CA2405946A1 (fr) | 2001-10-25 |
Family
ID=24194950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002405946A Abandoned CA2405946A1 (fr) | 2000-04-14 | 2001-04-13 | Procedes et compositions servant a traiter des etats fibreux et l'alteration de la fonction pulmonaire, et a ameliorer la production de lymphocyte |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001253468A1 (fr) |
| CA (1) | CA2405946A1 (fr) |
| WO (1) | WO2001079285A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0911945A2 (pt) | 2008-05-13 | 2015-10-13 | Clarassance Inc | cc10 humana recombinante e suas composições para uso no tratamento de rinite nasal |
| US9168285B2 (en) | 2009-10-15 | 2015-10-27 | Therabron Therapeutics, Inc. | Recombinant human CC10 protein for treatment of influenza and ebola |
| CN102834115B (zh) | 2009-10-15 | 2015-01-14 | 克拉莱森公司 | 用于治疗流感的重组人cc10蛋白 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354269A (en) * | 1991-12-20 | 1994-10-11 | Fibrogenex, Inc. | Method for treating cancer resections |
| US5696092A (en) * | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
-
2001
- 2001-04-13 AU AU2001253468A patent/AU2001253468A1/en not_active Abandoned
- 2001-04-13 WO PCT/US2001/012126 patent/WO2001079285A1/fr active Application Filing
- 2001-04-13 CA CA002405946A patent/CA2405946A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001079285A9 (fr) | 2003-02-06 |
| AU2001253468A1 (en) | 2001-10-30 |
| WO2001079285A1 (fr) | 2001-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100183640A1 (en) | Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production | |
| US10004784B2 (en) | Use of hepcidin as a regulator of iron homeostasis | |
| Rougier et al. | Human complement factor H deficiency associated with hemolytic uremic syndrome. | |
| Zuckerman et al. | A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis | |
| Mahadeva et al. | Polymers of Z α1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo | |
| JP2948910B2 (ja) | 遺伝子治療のためのアデノウイルスベクター | |
| WO2007109118A9 (fr) | Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique | |
| JP2002544286A (ja) | 免疫反応が十分に発揮し得ない個体の治療におけるマンナン結合性レクチン（ｍｂｌ）の新規適用 | |
| US20030008816A1 (en) | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production | |
| JP4885861B2 (ja) | 哺乳動物における細胞死または炎症を阻害する方法 | |
| US20020169108A1 (en) | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production | |
| US20220054654A1 (en) | Application of ecm1 in prevention and/or treatment of liver fibrosis-related diseases | |
| KR20010085294A (ko) | 염증성 및 섬유증성 증상의 치료에 있어서 재조합 인간유테로글로빈의 용도 | |
| US20040047857A1 (en) | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production | |
| CA2405946A1 (fr) | Procedes et compositions servant a traiter des etats fibreux et l'alteration de la fonction pulmonaire, et a ameliorer la production de lymphocyte | |
| EP1265627A2 (fr) | Procedes et compositions permettant d'inhiber l'angiogenese | |
| JP2005507941A (ja) | 肺気腫の予防および診断のためのサーファクタントプロテインｄ | |
| US7105496B2 (en) | Methods and compositions for inhibiting angiogenesis | |
| CN111770767A (zh) | 用于从生物流体中去除纤溶蛋白的体外设备和基质、其方法和用途 | |
| Yan et al. | Sorting of transgenic secretory proteins in miniature pig parotid glands following adenoviral‐mediated gene transfer | |
| JP4730967B2 (ja) | 血管平滑筋細胞の増殖阻害剤及び増殖促進剤のスクリーニング方法 | |
| Varsano et al. | Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. | |
| US20220401515A1 (en) | Application of non-igf1r-binding substance in prevention and/or treatment of inflammatory diseases | |
| US7749963B2 (en) | Isolated recombinant vaccinia virus complement control protein (hrVCP) polypeptide | |
| Chen et al. | The casein-derived peptide YFYPEL alleviates intestinal epithelial cell dysfunction associated with NEC by regulating the PI3K/AKT signaling pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |